Research comparison — no efficacy or outcome claims
Tirzepatide vs Retatrutide
Both compounds are long-acting acylated incretin-mimetic peptides from the same research lineage, and both are handled identically at the bench. The difference that matters is receptor coverage: tirzepatide engages two receptors, retatrutide three. Everything below compares them as laboratory materials — neither is sold for human or veterinary use, and nothing here is dosing guidance.
Side-by-side comparison
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Research code | LY3298176 | LY3437943 |
| Receptor targets | Dual agonist — GIP and GLP-1 receptors | Triple agonist — GIP, GLP-1 and glucagon receptors |
| Class | Acylated incretin-mimetic peptide | Acylated incretin-mimetic peptide |
| Reported half-life | ≈ 5 days (about 120 hours) | ≈ 6 days (about 144 hours) |
| Regulatory status | Approved for clinical indications elsewhere; supplied here for research only | Investigational, phase 3; supplied here for research only |
| Vial sizes stocked | 5, 10, 15, 20, 30, 60, 120 mg | 5 mg to 100 mg across eight sizes |
| Physical form | Lyophilised powder in a sealed vial | Lyophilised powder in a sealed vial |
| Reconstitution | Bacteriostatic water down the vial wall, gentle swirl | Bacteriostatic water down the vial wall, gentle swirl |
| Storage after mixing | 2–8 °C, protected from light, ~30-day window | 2–8 °C, protected from light, ~30-day window |
| Purity standard | ≥99.8% HPLC, batch-specific COA | ≥99.8% HPLC, batch-specific COA |
Receptor pharmacology
Tirzepatide is a single peptide chain that binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. In a research setting that makes it the standard tool for interrogating two-pathway incretin signalling with one molecule instead of co-administering two separate agonists.
Retatrutide keeps both of those arms and adds agonism at the glucagon receptor. The third receptor brings hepatic and energy-expenditure signalling into scope, which is why studies that need that axis select it. If a protocol has no glucagon-receptor question, the extra arm is a confound rather than a benefit — which is the practical reason many laboratories still choose tirzepatide.
Pharmacokinetics
Both peptides carry fatty-acid acylation, which promotes albumin binding and slows clearance. Published pharmacokinetic data put tirzepatide's half-life at roughly five days and retatrutide's at roughly six. Practically, both support the weekly study intervals used across the literature, and both reach steady state after several intervals rather than immediately — something to account for when designing a time-course experiment.
Handling, reconstitution and storage
There is no meaningful difference in technique. Both arrive as a lyophilised cake, are reconstituted with bacteriostatic water run down the vial wall, are swirled rather than shaken, and are refrigerated at 2–8 °C afterwards with a roughly 30-day in-use window. The only thing that changes between them is arithmetic, because the vial sizes differ.
Which one fits your study
- Two-pathway incretin work — tirzepatide, because it isolates GIP and GLP-1 without a glucagon variable.
- Glucagon-receptor involvement — retatrutide, which is the only triple agonist in our catalogue.
- Comparative signalling studies — both, run in parallel at matched concentrations.
- Reference material — tirzepatide has the deeper published dataset, which makes it the easier benchmark compound.
Both compounds, verified to the same standard
≥99.8% HPLC purity, batch-specific Certificate of Analysis, same-day dispatch before 2pm ET.
Tirzepatide vs retatrutide — FAQ
What is the difference between tirzepatide and retatrutide?
Tirzepatide (LY3298176) is a dual agonist at the GIP and GLP-1 receptors. Retatrutide (LY3437943) adds a third arm, the glucagon receptor, making it a triple agonist. That extra receptor is the defining structural and pharmacological difference between them.
Is tirzepatide or retatrutide better for research?
Neither is universally better and we make no potency or outcome claims. Laboratories choose by the signalling question: two-pathway work selects tirzepatide, while studies that need the glucagon receptor arm select retatrutide.
Do tirzepatide and retatrutide have different half-lives?
Both are long-acting acylated peptides. Published pharmacokinetic data put tirzepatide at roughly five days and retatrutide at roughly six days, so both support weekly study intervals in the literature.
Are tirzepatide and retatrutide reconstituted the same way?
The technique is identical: bacteriostatic water down the vial wall, gentle swirling, refrigerated storage after mixing. The arithmetic differs because the vial sizes differ — our tirzepatide line runs 5mg to 120mg and the retatrutide line runs 5mg to 100mg.
Which is approved — tirzepatide or retatrutide?
Tirzepatide has completed regulatory approval for clinical indications; retatrutide remains investigational and is in phase 3 trials. Neither compound sold here is approved for human or veterinary use — both are supplied for laboratory research only.
More tirzepatide research resources
All products and information on this page are supplied strictly for in vitro laboratory research by qualified professionals. Tirzepatide supplied here is a research chemical and is not sold for human or veterinary use. The figures on this page are reconstitution arithmetic, not dosing guidance — we do not provide therapeutic recommendations.